Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTP195183 Plus G-CSF for Stem Cell Mobilization
NCT00234169Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Oct 2005
- Primary completion
- Jan 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of irx-5183 in multiple myeloma (MM) and lymphoma (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Peripheral Blood CD34+ kinetics. Started Oct 2005; status: completed.
02
Drugs
irx-5183
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NCT00234169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234169.